ProMIS Neurosciences to present preclinical data on vaccines at AAN meeting

ProMIS Neurosciences (PMN) announced that the Company will present preclinical data on computationally-derived vaccines for neurodegenerative diseases at the American Academy of Neurology, AAN, Annual Meeting taking place from April 5-9, 2025 in San Diego. “We are excited to showcase the potential of our computational modeling platform for developing next-generation novel targeted vaccines to combat neurodegenerative diseases,” said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. “These promising preclinical data support our novel approach for the rational design of vaccines selectively targeting misfolded toxic proteins that drive neurodegenerative diseases. We look forward to advancing our mission to develop safe and effective vaccines that induce a specific immune response against toxic amyloid-beta oligomers for AD and against pathogenic species of alpha-synuclein for MSA and other synucleinopathies.”